Recent advances in combined modality therapy

Oncologist

Volumn 15, Issue 4, 2010, Pages 372-381

  Mierzwa, Michelle L ^a   Nyati, Mukesh K ^a   Morgan, Meredith A ^a   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Chemotherapy; Radiation; Radiosensitization; Targeted therapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CELL RECEPTOR; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PROCARBAZINE; TEMOZOLOMIDE;

ADD ON THERAPY; ARTICLE; BLOOD TOXICITY; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL IMMORTALIZATION; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG MEGADOSE; ESOPHAGUS CANCER; GASTROINTESTINAL TOXICITY; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PANCREAS CANCER; PRIORITY JOURNAL; RADIOSENSITIVITY; RECTUM CANCER; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 77951762464     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-S105     Document Type: Article

References (77)

1. Raymond E, Faivre S, Woynarowski JM et al. Oxaliplatin: Mechanism of action and antineoplastic activity. Semin Oncol 1998;25(suppl 5):4-12.
2. Blackstock AW, Hess S, Chaney S et al. Oxaliplatin: In vitro evidence of its radiation sensitizing activity-preclinical observations relevant to clinical trials. Int J Radiat Oncol Biol Phys 1999;46:724.
3. Pendyala L, Kidani Y, Perez R et al. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 1995;97:177-184.
4. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996;52:1855-1865.
5. Dunn TA, Schmoll HJ, Grnwald V et al. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Invest New Drugs 1997;15:109-114.
6. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350: 2343-2351.
7. Ryan DP, Niedzwiecki D, Hollis D et al. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. J Clin Oncol 2006;24:2557-2562.
8. Hospers GA, Punt CJ, Tesselaar ME et al. Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer: A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol 2007;14:2773-2779.
9. Roedel C, Arnold D, Hipp M et al. Multicenter phase II trial of preoperative radiotherapy with concurrent and adjuvant capecitabine and oxaliplatin in locally advanced rectal cancer. J Clin Oncol 2006;24(18 suppl):349.
10. Lawrence TS, Davis MA, Maybaum J. Dependence of 5-fluorouracil mediated radiosensitization on DNA-directed effects. Int J Radiat Oncol Biol Phys 1996;70:273-280.
11. Lawrence TS, Davis MA, Tang TY et al. Fluorodeoxyuridine-mediated cytotoxicity and radiosensitization requires S phase progression. Int J Radiat Oncol Biol Phys 1996;34:617-621.
12. Sawada N, Ishikawa T, Sekiguchi F et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999;5:2948-2953.
13. Saif MW, Eloubeidi MA, Russo S et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: Expression analysis of genes related to outcome. J Clin Oncol 2005; 23:8679-8687.
14. Schneider BJ, Ben-Josef E, McGinn CJ et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005;63:1325-1330.
15. Dunst J, Reese T, Sutter T et al. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J Clin Oncol 2002;20:3983-3991.
16. Shewach DS, Hahn TM, Chang E et al. Metabolism of 2,2 -difluoro-2 -deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218-3223.
17. Rockwell S, Grindley GB. Effect of 2,2 -difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro. Oncol Res 1992;4:151-155.
18. Lawrence TS, Chang EY, Hahn TM et al. Radiosensitization of pancreatic cancer cells by 2,2 -difluoro-2 -deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34:867-872.
19. Burris HA 3rd, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403-2413.
20. Loehrer PJ, Powell ME, Cardenes L et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized unresectable pancreatic cancer. J Clin Oncol 2008;26(15 suppl):4506.
21. Chauffert B, Mornex F, Bonnetain F et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008;19:1592-1599.
22. Wolff RA, Evans DB, Gravel DM et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001;7:2246-2253.
23. Muler JH, McGinn CJ, Normolle D et al. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol 2004;22:238-243.
24. Desai SP, Ben-Josef E, Normolle DP et al. Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer. J Clin Oncol 2007;25:4587-4592.
25. Murphy JD, Adusumilli S, Griffith KA et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007;68:801-808.
26. Ben-Josef E, Griffith K, Francis IR et al. Phase I radiation dose-escalation trial of intensity modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer. J Clin Oncol 2009;27(15 suppl):4602.
27. Regine WF, Winter KA, Abrams RA et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: A randomized controlled trial. JAMA 2008;299:1019-1026.
28. Allen AM, Zalupski MM, Robertson JM et al. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 2004;59:1461-1467.
29. Blanco R, Solé J, Montesinos J et al. Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: Final results of a phase II study. Lung Cancer 2008;62:62-71.
30. Socinski MA, Blackstock AW, Bogart JA et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26:2457-2463.
31. Choy H, Jain AK, Moughan J et al. RTOG 0017: A phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol 2009;4:80-86.
32. Arrieta O, Gallardo-Rincón D, Villarreal-Garza C et al. High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction gemcitabine and carboplatin. J Thorac Oncol 2009;4:845-852.
33. Zinner RG, Komaki R, Cox JD et al. Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: A phase I trial in patients with stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2009;73:119-127.
34. Rao S, Krauss NE, Heerding JM et al. 3 -(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. J Biol Chem 1994; 269:3132-3134.
35. Manfredt JJ, Horwitz SB. Taxol: An antimitotic agent with a new mechanism of action. Pharmacol Ther 1984;25:83-125.
36. Milas L, Hunter NR, Mason KA et al. Role of reoxygenation in induction of enhancement of tumor response by paclitaxel. Cancer Res 1995;55:3564-3568.
37. Feng FY, Varambally S, Tomlins SA et al. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 2007;26:3431-3439.
38. Belani CP, Choy H, Bonomi P et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: A randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-5891.
39. Akerley BW, Herndon J, Turrisi AT et al. Induction chemotherapy with paclitaxel and carboplatin followed by concurrent thoracic radiotherapy and weekly PC for patients with unresectable stage III non-small cell lung cancer: Preliminary analysis of a phase II trial by the CALGB [abstract 1915]. Proc Am Soc Clin Oncol 2000;19.
40. Vokes EE, Herndon J, Kelley MJ et al. Induction chemotherapy followed by concomitant chemoradiotherapy (CT/XRT) versus CT/XRT alone for regionally advanced unresectable non-small cell lung cancer: Initial analysis of a randomized phase III trial. J Clin Oncol 2004;22(14 suppl):7005.
41. Cmelak AJ, Li S, Goldwasser MA et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cellcarcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 2007;25:3971-3977.
42. Agarwala SS, Cano E, Heron DE et al. Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer. Ann Oncol 2007;18:1224-1229.
43. Chougule PB, Akhtar MS, Rathore R et al. Concurrent chemoradiotherapy with weekly paclitaxel and carboplatin for locally advanced head and neck caner: Long-term follow-up of a Brown University Oncology Group phase II study (HN-53). Head Neck 2008;30:289-296.
44. Salama JK, Stenson KM, Kistner EO et al. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: A multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 2008;19:1787-1794.
45. Donson AM, Addo-Yobo SO, Handler MH et al. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer 2007;48:403-407.
46. Friedman HS, Dolan ME, Pegg AE et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995;55:2853-2857.
47. Wedge SR, Porteous JK, Newlands ES. Effect of single and multiple administration of an O6-benzylguanine/temozolomide combination: An evaluation in a human melanoma xenograft model. Cancer Chemother Pharmacol 1997;40:266-272.
48. Yung WK, Albright RE, Olson J et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-593.
49. Stupp R, Dietrich PY, Ostermann Kraljevic S et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-1382.
50. Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996.
51. Addeo R, De Rosa C, Faiola V et al. Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for nonsmall cell lung cancer and breast cancer patients with brain metastases. Cancer 2008;113:2524-2531.
52. Kumar B, Cordell KG, Lee JS et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008;26:3128-3137.
53. Pivot X, Magné N, Guardiola E et al. Prognostic impact of the epidermal growth factor rector levels for patients with larynx and hypopharynx cancer. Oral Oncol 2005;41:320-327.
54. Nyati MK, Morgan MA, Feng FY et al. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 2006;6:876-885.
55. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Eng J Med 2006;354:567-578.
56. Hughes S, Liong J, Miah A et al. A brief report on the safety of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer (NSCLC): SCRATCH study. J Thor Oncol 2008;3:648-651.
57. Jensen AD, Munter MW, Bischoff H et al. Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: The NEAR protocol (NCT00115518). BMC Cancer 2006;6:122.
58. Munter M, Timke C, Abdollahi A et al. Final results of a phase II trial for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine. J Clin Oncol 2008;26(15 suppl):4613.
59. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359: 1757-1765.
60. Chun PY, Feng FY, Scheurer AM et al. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 2006;66:981-988.
61. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 1. J Clin Oncol 2004;22:777-784.
62. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
63. Langer CJ. The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol 2009;27:1350-1354.
64. Ahsan A, Hiniker SM, Davis MA et al. Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization. Cancer Res 2009;69:5108-5114.
65. Stinchcombe TE, Morris DE, Lee CB et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimensional conformal thoracic radiotherapy with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 2008;3:250-257.
66. Ahmed SM, Cohen EE, Haraf DJ et al. Updated results of a phase II trial integrating gefitinib into concurrent chemoradiation followed by G adjuvant therapy for locally advanced head and neck cancer. J Clin Oncol 2007; 25(18 suppl):6028.
67. Van Triest B, Kuenen B, Ghotra V et al. Feasibility study of erlotinib plus radiotherapy in patients with locally advanced or recurrent rectal carcinoma [abstract 153]. Int J Radiat Oncol Biol Phys 2008;72 (suppl 1):S69.
68. Brown PD, Krishnan S, Sarkaria JN et al. Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008;26:5603-5609.
69. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-1966.
70. Willett CG, Boucher Y, di Tomaso E et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147.
71. Crane CH, Eng C, Feig BW et al. Phase II trial of neoadjuvant bevacizumab, capecitabine and radiotherapy for locally advanced rectal cancer. J Clin Oncol 2008;26(15 suppl):4091.
72. Kirkpatrick JP, Desjardins A, Reardon DA et al. Radiotherapy, temozolomide and bevacizumab followed by irinotecan, temozolomide and bevacizumab in newly diagnosed glioblastoma mutliforme: Preliminary results from an ongoing phase II trial [abstract 2089]. Int J Radiat Oncol Biol Phys 2008;72(1 suppl):S209.
73. Small W, Mulcahy M, Rademaker A et al. A phase II trial of weekly gemcitabine and bevacizumab in combination with abdominal radiation therapy in patients with localized pancreatic cancer [abstract 13]. Int J Radiat Oncol Biol Phys 2008;72(1 suppl):S6.
74. Varadhachary GR, Wolff RA, Crane CH et al. Preoperative gemcitabine and bevacizumab-based chemoradiation for resectable pancreatic adenocarcinoma. J Clin Oncol 2008;26(15 suppl):4630.
75. Crane CH, Ellis LM, Abbruzzese JL et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol 2006;24:1145-1151.
76. Morgan MA, Parsels LA, Kollar LE et al. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res 2008;14:5142-5149.
77. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-2799.